Aptamer developed by HKBU for treating rare bone disease 'X-linked hypophosphatemia ...
HKBU's aptamer for treating X-linked hypophosphatemia (XLH) received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA. The aptamer, Apc001, targets sclerostin's loop3 domain to promote bone formation without cardiovascular risks, and is set for clinical trials in China and the U.S.
Highlighted Terms
Related News
Aptamer developed by HKBU for treating rare bone disease 'X-linked hypophosphatemia ...
HKBU's aptamer for treating X-linked hypophosphatemia (XLH) received Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA. The aptamer, Apc001, targets sclerostin's loop3 domain to promote bone formation without cardiovascular risks, and is set for clinical trials in China and the U.S.